Pre-embedding immunogold labeling to optimize protein localization at subcellular compartments and membrane microdomains of leukocytes by Melo, Rossana et al.
Pre-embedding immunogold labeling
to optimize protein localization
at subcellular compartments and
membrane microdomains of leukocytes
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Melo, Rossana C N, Ellen Morgan, Rita Monahan-Earley,
Ann M Dvorak, and Peter F Weller. 2014. Pre-embedding
immunogold labeling to optimize protein localization at subcellular
compartments and membrane microdomains of leukocytes. Nature
Protocols 9, no. 10: 2382–2394. doi:10.1038/nprot.2014.163.
Published Version doi:10.1038/nprot.2014.163
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32306657
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
Pre-embedding immunogold labeling to optimize protein 
localization at subcellular compartments and membrane 
microdomains of leukocytes
Rossana C N Melo1,2, Ellen Morgan3, Rita Monahan-Earley3, Ann M Dvorak3, and Peter F 
Weller2
1Laboratory of Cellular Biology, Department of Biology, Federal University of Juiz de Fora, Juiz de 
Fora, Minas Gerais, Brazil
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, Massachusetts, USA
3Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, Massachusetts, USA
Abstract
Precise immunolocalization of proteins within a cell is central to understanding cell processes and 
functions such as intracellular trafficking and secretion of molecules during immune responses. 
Here we describe a protocol for ultrastructural detection of proteins in leukocytes. The method 
uses a pre-embedding approach (immunolabeling before standard processing for transmission 
electron microscopy (TEM)). This protocol combines several strategies for ultrastructure and 
antigen preservation, robust blocking of nonspecific binding sites, as well as superior antibody 
penetration for detecting molecules at subcellular compartments and membrane microdomains. A 
further advantage of this technique is that electron microscopy (EM) processing is quick. This 
method has been used to study leukocyte biology, and it has helped demonstrate how activated 
leukocytes deliver specific cargos. It may also potentially be applied to a variety of different cell 
types. Excluding the initial time required for sample preparation (15 h) and the final resin 
polymerization step (16 h), the protocol (immunolabeling and EM procedures) can be completed 
in 8 h.
INTRODUCTION
TEM is an outstanding tool for providing a comprehensive view of the interior of a cell at 
the nanometer scale, and it continues to have a crucial role in biological research and 
© 2014 Nature America, Inc. All rights reserved.
Correspondence should be addressed to R.C.N.M., rossana.melo@ufjf.edu.br. 
AUTHOR CONTRIBUTIONS R.C.N.M., A.M.D. and P.F.W. designed the experiments. R.C.N.M. carried out sample preparation, 
immunolabeling and electron microscopic processing and analyses. E.M. and R.M.-E. provided technical assistance. E.M. carried out 
ultramicrotomy. All authors wrote the paper.
COMPETING FINANCIALINTERESTS The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.
NIH Public Access
Author Manuscript
Nat Protoc. Author manuscript; available in PMC 2015 April 01.
Published in final edited form as:
Nat Protoc. 2014 October ; 9(10): 2382–2394. doi:10.1038/nprot.2014.163.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
diagnostic pathology1–6. When combined with molecular detection methods, EM is the only 
technique with sufficient resolution to localize proteins to intracellular compartments and 
small membrane domains2. Visualization of specific proteins is achieved with electron-
dense markers, usually gold particles, conjugated to secondary antibodies, and for this 
reason antigen labeling at the ultrastructural level is termed immunogold EM (Fig. 1).
Rationale for detecting antigens before embedding for EM
Immunogold EM has provided substantial insights into the cellular content of biomolecules 
and to cell function, but it involves many technical challenges and is considered one of the 
most laborious techniques in cell biology. The main challenge of immunogold EM is to 
provide both sensitive antigen detection and detailed information on the cell structure; 
however, these are conflicting technical situations. Antigen preservation may be hampered 
by optimal cell fixation and by dehydration and resin embedding, conventional procedures 
for EM, resulting in weak or negative labeling. Thus, antigens may not be detected by 
postembedding immunogold EM (i.e., by labeling on the surface of a thin section after EM 
procedures7). In addition to affecting antigenicity, labeling is restricted to the thin section 
surface because antibodies cannot penetrate into the resin7,8. Postembedding immunogold 
EM has been used since the 1970s, and it is mostly convenient for detecting abundant 
antigens9. An alternative method is pre-embedding immunogold EM (immunolabeling 
before the specimens are embedded in resin), which enables improved antigen preservation. 
Pre-embedding immunogold EM has been effectively applied to different biological 
systems7,10–13. Our group has been working with both post- and pre-embedding 
immunogold EM approaches for many years. We have localized enzymes involved in 
inflammatory pathways within leukocytes using postembedding methods14,15, but we have 
failed to detect intracellular sites of interleukins in the same cells using this approach.
Choice of antigen probe
In addition to choosing between a post- and a pre-embedding approach, there are other 
issues to consider to ensure a successful protein immunolocalization study of cells and 
tissues at the ultrastructural level. For precise molecular information integrated with cellular 
architecture, antibodies have to access small membrane domains. Antibody probes 
conjugated with colloidal gold particles are too large (~5–25 nm) to freely penetrate into 
cells, even after permeabilization of the cellular membrane8,16. Therefore, to access vesicles 
and other microdomains, the smallest gold particles should be used12,17. Our protocol uses 
very small gold particles (1.4 nm in diameter) covalently conjugated with Fab fragments 
(Fig. 1), which are only one-third the size of a whole IgG molecule. These very small probes 
improve antibody penetration and provide more quantitative labeling of antigenic sites8,18, 
with access to membrane microdomains. Therefore, in addition to optimal epitope 
preservation, this protocol provides excellent access of the antibodies to cell 
subcompartments. This is important for the identification of small molecules such as those 
of the immune signaling system that are not usually detected by postembedding EM.
Different cell types can also present unique challenges. In cells from the immune system, 
such as neutrophils, eosinophils and macrophages, precise immunolocalization of proteins is 
especially important for understanding intracellular trafficking and the secretion 
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mechanisms of immune mediators. However, handling can easily activate these cells 
inappropriately. Moreover, leukocytes such as eosinophils store a multitude of preformed 
immune mediators and other molecules within cytoplasmic compartments19. Apparent 
labeling of these sites can be confused with nonspecific immunolabeling, resulting in strong 
background formation.
Applications of the protocol
Our methodology was primarily developed for studying human leukocytes isolated from the 
peripheral blood17,20–22, but it is probably applicable to virtually any cell suspension with a 
few additional modifications. Applied to leukocytes, the technique has been used to 
characterize the intracellular localization of cytokines, immune cell signaling molecules and 
tetraspanins17,20–25. Because vesicular traffic from secretory granules underlies secretion in 
different cell types, including leukocytes, a challenge to understanding this secretory 
pathway in more detail has been the identification of granule-derived products within 
transport vesicles. This protocol enabled the first ultrastructural identification of a vesicle-
based transport of interleukin-4 (IL-4; ref. 20) and major basic protein-1 (MBP-1; ref. 17) 
from eosinophil secretory granules. The existence of vesicle-mediated secretion from 
leukocyte secretory granules has been previously underestimated, probably because of 
technical issues: inadequate preservation of vesicles and/or inability of antibodies to access 
them.
The protocol has also been used to study the intracellular traffic of cytokine receptors, such 
as IL-4Rα (ref. 21) and Notch signaling molecules22. The identification of previously 
unrecognized pools of cytokine receptors such as IL-4R revealed a unique mechanism 
contributing to the specificity of cytokine secretion. We also showed for the first time that 
human blood eosinophils express Notch receptors and Notch ligands22.
The methodology has also been used to ascertain localization of tetraspanins such as CD63 
and CD9 (refs. 17,24,26) and protein disulfide isomerase (PDI)27 in leukocytes. We 
demonstrated that CD9 is abundant on the surface of eosinophil leukocytes, presenting the 
first EM data of the ultrastructural immunolocalization of CD9 in human eosinophils, which 
represents a novel insight into the organization of the antigen presentation complex of these 
cells24. The technique has also been applied to the study of molecules involved in the 
endocytic pathway such as Rab7 and LC3, labeled in phagosomes within macrophages 
infected with mycobacteria (R.C.N.M., unpublished observations). Therefore, the main uses 
of this technique involve studies focused on cellular immunology, innate and adaptive 
immunity, immune responses to pathogens, immunopathology and inflammatory responses. 
Beyond its use in these fields, the technique is applicable to the immunolocalizaton of a 
wide range of proteins within varied cell types.
Limitations
One limitation of this protocol is that it does not facilitate colocalization studies (i.e., 
simultaneous observation of two epitopes), which can be achieved with postembedding EM 
using larger gold probes with different sizes.
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Experimental design
This protocol describes a pre-embedding immunogold EM protocol for the detection of 
proteins in leukocytes. Our methodology, a combination of different strategies for optimal 
labeling and morphology preservation, has been used for almost 10 years (refs. 17,20–
24,27). Figure 2 presents a summary of all the stages of the protocol.
Sample fixation—Because paraformaldehyde has less effect on antigenicity, our 
experience is that most cells should be first fixed with this fixative alone, labeled and then 
re-fixed with glutaraldehyde, which is a strong cross-linker of proteins and provides best 
structural preservation, but is known to lower protein antigenicity28. However, a 
combination of both aldehydes may work for certain antigens. We were not able to detect 
interleukins within leukocytes even when small amounts of glutaraldehyde (0.1%, vol/vol) 
were used. However, in our hands, MBP-1 was clearly labeled within human leukocytes by 
using high concentrations of glutaraldehyde. Therefore, because this protocol can be applied 
to different cell types and antigens, optimization of the best fixative may be necessary to 
adapt the protocol to a specific experimental condition. To strive for the best structural 
preservation, the fixative should be freshly prepared and added directly and gently to the cell 
suspension; i.e., it is not necessary to centrifuge the cells into a pellet before fixation. 
Moreover, we do not use a high centrifugation speed (1,000g) for the subsequent step of cell 
washing with buffer. After fixation, isolated cells are pre-embedded in agar to facilitate cell 
processing and to prevent mechanically induced artifacts. Our experience is mostly with 
cells in suspension (such as leukocytes isolated from the peripheral blood or pleural cavity), 
but we were also successful in labeling antigens in tissue fragments using this methodology. 
After fixation, samples must be immersed in 30% (wt/vol) sucrose overnight to avoid ice 
crystal formation during freezing. Storage in liquid nitrogen is preferable to −80 °C because 
ice crystals can still be formed at this temperature. Our experience is that samples stored in 
liquid nitrogen can be stored for years and assessed for different antigen immunolocalization 
studies. This is particularly important for precious human samples.
Immunolabeling—Our approach performs immunolabeling on 10-μm-thick cryostat 
sections, which enable antibody penetration throughout the section thickness, as previously 
reported29. Therefore, it is not necessary to include a permeabilization step, as required for 
whole cells30. The permeabilization step, which can interfere with the structural integrity of 
membranes, can be detrimental to the ultrastructure, and thus it is best avoided. Thicker 
sections are not adequate, as the antibody penetration may be restricted. Sections are 
collected on special glass slides. Regular uncoated glass slides will not allow adequate 
adhesion of the cells to the slide surface. Before immunolabeling, nonspecific binding sites 
need to be blocked. Blocking is particularly important because immunolabeling of 
leukocytes can result in a strong and unexpected background formation. We use two steps of 
blocking buffers before incubation with the primary antibody.
Silver enhancement—This stage consists of incubation with a silver enhancement 
solution according to the manufacturer’s instructions, and it enables nucleation of silver ions 
around gold particles. These ions precipitate as silver metal, and the particles grow in size 
facilitating observation under TEM. Before silver enhancement, cells are sequentially 
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transferred to distilled water because buffer traces can interfere with the silver enhancement 
process. Therefore, adequate washing in distilled water must be done before this step. The 
silver enhancement solution is stored at −20 °C, but it is used at room temperature (20 °C). 
Therefore, keep in mind that it is necessary to thaw the solution kit before this step. 
Moreover, the solution is light-sensitive, and the incubation is done in a dark room. We have 
found that 10 min of incubation is ideal for optimal visualization of the tested antibodies 
(Table 1) in leukocytes. However, this time can be changed depending on the antigen. The 
silver layer covering the gold particles is sensitive to the action of osmium tetroxide, which 
can induce particle loss. To prevent this, our approach uses a procedure with sodium 
thiosulfate after the silver enhancement step in order to stabilize the silver-enhanced 
immunogold particles. Moreover, the time of treatment with osmium tetroxide is just 10 
min.
Processing for EM—This stage involves conventional procedures for EM (postfixation 
with osmium tetroxide, en bloc staining with uranyl acetate, dehydration in alcohol, 
infiltration and embedding in resin), which is usually time-consuming. Our technique uses a 
faster infiltration/embedding step compared with most immunoEM procedures, which use an 
overnight infiltration stage. We have found that 15 min is adequate for the subsequent 
embedding step.
Ultrathin sectioning—Thin (~80 nm) sections are obtained directly from the block 
surfaces without the need to cut thick 1-μm sections. Sections are mounted on uncoated 200-
mesh copper grids, stained with lead citrate only and viewed with a transmission electron 
microscope.
MATERIALS
REAGENTS
• Leukocyte suspensions or tissue of interest ▲ CRITICAL Samples must be 
obtained in accordance with governmental and institutional regulations.
• Na2HPO4·7H2O (Fisher Scientific, cat. no. S373)
• NaH2PO4·H2O (Fisher Scientific, cat. no. S369)
• NaCl (Fisher Scientific, cat. no. S640)
• Paraformaldehyde (Electron Microscopy Sciences, cat. no. 19208) ! CAUTION 
Paraformaldehyde is toxic. Use the reagent in a hood and handle it with gloves.
• Agar (Bacto-agar, BD Biosciences, cat. no. 214010)
• Sucrose (Sigma-Aldrich, cat. no. S9378)
• Tissue-Tek O.C.T. compound (Fisher Scientific, cat. no. 14-373-65)
• Toluidine blue O (Fisher Scientific, cat. no. T-161)
• Sodium tetraborate (Electron Microscopy Sciences, cat. no. 21130)
• Mounting medium (Permount, Fisher Scientific, cat. no. SP15-500)
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• Gelatin (Sigma-Aldrich, cat. no. G6650)
• Glycine (Sigma-Aldrich, cat. no. G7403)
• BSA (Electron Microscopy Sciences, cat. no. 25554)
• Normal goat serum (NGS; Jackson ImmunoResearch, cat. no. 005-000-121)
• Appropriate primary antibodies (see Table 1 for a list of antibodies we used)
• Secondary antibodies (Fab fragments conjugated with 1.4-nm gold particles; 
Nanogold, Nanoprobes, cat. nos. 2002 (anti-mouse), 2004 (anti-rabbit), 2008 (anti-
rat), 2055 (anti-guinea pig) and 2006 (anti-goat), depending on the primary 
antibody host species). We tested all of these ourselves
• Glutaraldehyde, EM grade, 50% (wt/vol) aqueous (Electron Microscopy Sciences, 
cat. no. 16310) ! CAUTION Glutaraldehyde is toxic. Use the reagent in a hood and 
handle it with gloves.
• Silver enhancement (HQ Silver, Nanoprobes, cat. no. 2012)
• Sodium thiosulfate (Sigma-Aldrich, cat. no. 563188)
• Osmium tetroxide, secondary fixative (Electron Microscopy Sciences, cat. no. 
19100) ! CAUTION Osmium tetroxide is toxic. Use the reagent in a hood and 
handle it with gloves.
• Uranyl acetate (Electron Microscopy Sciences, cat. no. 22400) ! CAUTION 
Uranyl acetate is toxic and slightly radioactive. Use the reagent in a hood and 
handle it with gloves.
• Ethanol: 70, 95 and 100% (vol/vol)
• Eponate 12 resin (Ted Pella, cat. no. 18005) ! CAUTION Eponate 12 is a severe 
irritant to the eyes, skin and nasal passages. Use the reagent in a fume hood and 
handle it with gloves.
• Nadic methyl anhydride (NMA-4; Electron Microscopy Sciences, cat. no. 19000) ! 
CAUTION NMA is a severe irritant to the eyes and respiratory tract. Do not 
breathe the vapor. Use the reagent in a hood and handle it with gloves.
• Dodecenylsuccinic anhydride (DDSA; Ted Pella, cat. no. 18022) ! CAUTION 
DDSA is a severe irritant to the eyes and skin. Use the reagent in a fume hood and 
handle it with gloves.
• Propylene oxide (Fisher Scientific, cat. no. 04332-1)
! CAUTION Propylene oxide is highly flammable and a severe irritant to the eyes, 
skin and nasal passages. Use the reagent in a fume hood and handle it with gloves.
• 2,4,6-Tri(dimethylaminoethyl)phenol (DMP-30; Electron Microscopy Sciences, 
cat. no. 13600) ! CAUTION DMP-30 is a severe irritant to the eyes, skin and nasal 
passages. Use the reagent in a fume hood and handle it with gloves.
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• Lead citrate (Electron Microscopy Sciences, cat. no. 17800) ! CAUTION lead 
citrate is toxic. Use the reagent in a hood and handle it with gloves.
EQUIPMENT
• Balance
• Magnetic stir bars
• Magnetic stirrer
• Fume hood
• Microcentrifuge
• Microcentrifuge tubes, 300-μl
• Pointed applicator sticks
• Parafilm M (Electron Microscopy Sciences, cat. no. 70990)
• Superfrost Plus microscope slides (Fisher Scientific, cat. no. 12-550-15)
• Coverslips
• Microtome blades (Leica 818, Electron Microscopy Sciences, cat. no. 63065-HP)
• Diamond scriber pen (Ted Pella, cat. no. 54463)
• Disposable razor blades
• Fine-tipped tweezers (Electron Microscopy Sciences, cat. no. 78518-3, ultra-fine)
• Regular tweezers
• Dental wax
• Syringe filters, 0.2 μm (Fisher Scientific, cat. no. 09-719C)
• Syringes without needles, 1 and 10 ml (BD Biosciences, cat. no. 309628 and 
309604)
• Cryostat
• Hot plate
• Shaker
• Stain moisture chambers, clear (Electron Microscopy Sciences, cat. no. 62010-35)
• Stain moisture chamber, black with black lid (Electron Microscopy Sciences, cat. 
no. 71396-B)
• Glass test tubes with screw caps
• Ultramicrotome (Leica)
• Diamond knife (DiATOME)
• Filter paper, hardened
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• Petri dish filled with dental wax or paraffin
• Copper mesh grids (Electron Microscopy Sciences, cat. no. G200-Cu)
• Micropipetters
• Pipette tips
• Liquid nitrogen container
• BROWN wide-mouthed plastic bottle (Nalgene, cat. no. 03-313-3E)
• BEEM embedding capsules (Ted Pella, cat. no. 130-1)
• BEEM capsule press (Electron Microscopy Sciences, cat. no. 69920-00)
• Light microscope
• Perfect loop (Electron Microscopy Sciences, cat. no. 70616-HD)
• Transmission electron microscope
REAGENT SETUP
PBS (0.02 M, 0.15 M NaCl, pH 7.4)—Prepare a stock solution of 0.2 M phosphate buffer 
by dissolving 2.75 g of NaH2PO4·H2O in 100 ml of double-distilled water (part 1) and 5.36 
g of Na2HPO4·7H2O in 100 ml of double-distilled water (part 2). Mix 19 ml of part 1 and 81 
ml of part 2. Bring the mixture to a final volume of 1 liter (10 × dilution) with double-
distilled water to achieve a final concentration of 0.02 M. Add 8.76 g of NaCl, stir and 
adjust the pH to 7.4. Cover the solution with Parafilm and refrigerate it. This solution can be 
stored at 4 °C for up to 3 months.
Paraformaldehyde and glutaraldehyde, primary fixative—The initial fixative is 
generally 4% (wt/vol) paraformaldehyde in 0.02 M PBS and 0.15 M NaCl (pH 7.4). In the 
hood, add 4 g of paraformaldehyde in 80 ml of PBS. Add 3 drops of 1 M NaOH. Heat the 
mixture while stirring to ~60 °C until the solution is clear. Take care that the solution does 
not boil. Note that the powder will not immediately dissolve. Cool it under running water. 
Adjust the volume to 100 ml using the same buffer. Check the pH and adjust the pH to 7.4. 
Cover the flask with Parafilm. Glutaraldehyde fixative at 2% (vol/vol) in distilled water is 
used after immunolabeling. For 50 ml of fixative, mix 2 ml of stock of 50% (vol/vol) 
glutaraldehyde and 48 ml of distilled water. The most effective fixative must be determined 
experimentally. There are several other glutaraldehyde/paraformaldehyde combinations in 
use depending on the antigen to be investigated, such as 4% (wt/vol) paraformaldehyde and 
0.1% glutaraldehyde (vol/vol) in the same buffer. ! CAUTION Glutaraldehyde and 
paraformaldehyde are irritants to the eyes, skin and respiratory tract. Use them under a fume 
hood. ▲ CRITICAL Fixatives should be freshly prepared for every experiment to allow 
optimal fixation.
PBS-glycine solution (0.05 M glycine)—Mix 0.75 g of glycine in 200 ml of 0.02 M 
PBS (pH 7.4), stir and cover the mixture with Parafilm. For 100 ml, use 0.375 g. ▲ 
CRITICAL Use a freshly prepared solution.
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PBS-gelatin-BSA buffer—The first blocking buffer is prepared by mixing 0.1% (wt/vol) 
gelatin in 0.02 M PBS (pH 7.4) under stirring and minor heating (~40 °C). Wait for 
complete gelatin melting, cover it with Parafilm and cool it in the refrigerator. After cooling, 
add 1% (wt/vol) BSA, gently stir, cover it with Parafilm and refrigerate it. ▲ CRITICAL 
Take out any foam formed during buffer preparation. The solution should be clean and 
slightly yellow. This solution can be stored at 4 °C for up to 1 month.
PBS-gelatin-BSA-NGS buffer—The second blocking buffer is prepared by mixing NGS 
with PBS-gelatin-BSA buffer. Reconstitute NGS by adding 10 ml of syringe-filtered 
distilled water into the lyophilized NGS vial. Wait for it dissolve, and then mix 10 ml of 
NGS and 90 ml of PBS-BSA buffer. Gently stir the mixture, cover it with Parafilm and 
refrigerate it. This solution can be stored at 4 °C for up to 2 weeks.
Sodium thiosulfate—This solution is prepared at 3% (vol/vol) in distilled water. ▲ 
CRITICAL Use a freshly prepared solution. Do not store the solution.
Osmium tetroxide, secondary fixative—The secondary fixative is 1% (wt/vol) 
osmium tetroxide in distilled water (just mix osmium stock solution and water 1:1 at the 
time of use). Stock solution is prepared at 2% (wt/vol; 1 g of osmium in 50 ml of water). 
File the neck of the ampoule containing osmium to weaken it. Break open carefully using 
the ampoule breaker. Pipette a small amount of water into the ampoule to dissolve the 
osmium. Place it in the stoppered bottle. Add the remaining water. Wrap the stopper with 
Parafilm and the whole bottle and stopper with foil to keep it light-tight. Keep the bottle in 
the fume hood for 1–2 d, swirling it occasionally to dissolve the contents. Filter all the 
newly made osmium tetroxide into a light-tight stock bottle. This stock solution can be 
stored at 4 °C for up to 6 months. ! CAUTION Osmium tetroxide is very toxic, and it can 
cause severe eye and skin burns, acute lung congestion and temporary blindness. Use it 
under a fume hood and handle it while wearing gloves. ▲ CRITICAL Osmium should be 
clear and slightly yellow. Anything other than this is considered contaminated, and it should 
not be put into the stock bottle or be used in any way. To dispose of used or contaminated 
osmium, pour it into an osmium waste bottle containing a layer of cooking or vegetable oil 
to neutralize the osmium.
HQ silver enhancement—The system consists of three reagents supplied in dropping 
bottles: initiator, moderator and activator. The working solution is prepared by combining 
equal volumes of each component as per the manufacturer’s instructions immediately before 
use. For five slides, we used 40 drops of each component. Mix the initiator and moderator 
thoroughly, and then add the activator and mix it thoroughly again. ▲ CRITICAL The 
components are stored at −20 °C; thaw and allow the components to reach to room 
temperature before use (at least 2 h). The moderator and activator are viscous; mixing will 
be easier if the components are allowed to reach room temperature first. Avoid cross-
contamination of the enhancer and initiator solutions: to prevent replacing the caps on the 
wrong bottles, the cap of the initiator is red, whereas that of the activator is blue. The 
solutions are light-sensitive. Silver enhancement must be carried out in a darkroom. A 
safelight or other darkroom light may be used. Do not expose these reagents to heat. Avoid 
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contact with metallic objects, as these can induce silver precipitation. Avoid skin contact: 
the silver enhancement reagents will stain the skin.
Uranyl acetate en bloc contrast-enhancing agent—Dissolve 1% (wt/vol) uranyl 
acetate in distilled water by mixing the powder with water in a glass test tube with a screw 
cap. Close the tube, cover the screw cap with Parafilm and place it on the center of the 
shaker at medium speed tied with a tape to completely dissolve the contents. The solution 
should be freshly prepared. ! CAUTION Uranyl acetate is slightly radioactive and toxic if 
ingested, inhaled or absorbed. Effects are cumulative. Use it under a fume hood and handle 
it while wearing gloves. ▲ CRITICAL Use a freshly prepared solution.
Eponate stock—Measure in dry glass graduated cylinders 183.5 ml of Eponate 12 resin 
plus 175 ml of DDSA and 67 ml of NMA, and then mix them directly in a brown wide-
mouthed plastic bottle. Take time to drain all the contents well. Accuracy in measurement is 
crucial for the appropriate hardness of the blocks. Keep everything very dry while making 
this. Shake the mixture by hand for ~15 min, and then place it on the center of the shaker at 
a vigorous speed for the rest of the day. Store it at 4 °C tightly capped. Eponate can be 
stored at 4 °C for up to 6 months. ! CAUTION Eponate, DDSA and NMA are toxic and 
carcinogenic. They are strong skin irritants, and they are respiratory tract irritants if inhaled. 
Use them under a fume hood and handle them while wearing gloves.
Eponate embedding medium—Remove stock Eponate from the refrigerator early and 
allow it to equilibrate to room temperature (~30 min–1 h). Measure the amount of Eponate 
needed in a plastic tri-pour. By using a 1-ml syringe, pull up some DMP-30 a few times to 
lubricate the syringe to be sure that the measurement will be accurate, and add the 
appropriate amount to the Eponate. For each 25 ml of Eponate add 0.5 ml of DMP-30. Make 
at least 25 ml for every experiment. Stir it thoroughly with a glass rod for 5 min. This 
solution must be freshly prepared before use. The remaining solution can be stored in 
labeled syringes in the freezer (−20 °C) to use in the infiltration step in a future run. ! 
CAUTION Eponate is toxic. It is a strong skin irritant, and it is a respiratory tract irritant if 
inhaled. Use it under a fume hood and handle it while wearing gloves.
Lead citrate contrast-enhancing (stain) agent—Weigh 0.125 g of lead citrate and 
dilute it in 5 ml of 1 N NaOH in a volumetric flask. Fill the flask to 50 ml with double-
distilled water, and then stopper the flask. Use a flea-sized stir bar to stir the mixture to 
dissolve the lead citrate. Filter the solution using the large hardened filter paper into a red 
volumetric flask. This solution can be stored at room temperature for up to 6 months. ! 
CAUTION Lead citrate is very toxic if it is inhaled or ingested. Contact with skin may 
cause lead poisoning. Effects are cumulative. Use it under a fume hood and handle it while 
wearing gloves. ▲ CRITICAL Be careful not to breathe on it. Expired CO2 may cause the 
lead to form crystals, which act as an artifact and can contaminate the surface of the thin 
section on the grid.
Toluidine blue, 0.5% (wt/vol)—Mix 1.0 g of sodium borate in 200 ml of double-distilled 
water. Add 1.0 g of toluidine blue slowly while it is on the stirring plate. Filter and store the 
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solution in a brown bottle. This solution is stable and can be stored at room temperature for 
many months, but it should be filtered through a syringe (0.2-μm filter) or hardened filter 
paper before use.
PROCEDURE
Sample preparation ● TIMING ~15 h
1| Fix the samples. Follow option A for cells in suspension and option B for 
tissues.
A. For cells in suspension
i. Carefully add the primary fixative directly on the cell 
suspension in plastic 10-ml test tubes. For 1–2 ml of cell 
suspension (for example, obtained after leukocyte 
isolation from the peripheral blood or cavity lavages), fill 
the tube to 10 ml with the fixative.
▲ CRITICAL STEP The amount of cells is crucial for 
obtaining a good visible pellet. In our experience, 3 
million cells is the minimum necessary to make one 
reasonable pellet. However, it is desirable to have more 
cells and to prepare a more substantial pellet for better 
visualization during sectioning and processing. Moreover, 
at least two pellets for each condition should be prepared, 
if possible, in case something unexpected happens during 
processing.
ii. Rock the tube gently and fix for 30 min at room 
temperature.
iii. Remove the fixative by centrifugation at 1,000g for 10 
min at room temperature.
iv. Wash the samples in PBS 0.02 M buffer and then 
resuspend the cells in a small amount of buffer (~500 μl–1 
ml) to facilitate subsequent preparation of agar pellets.
? TROUBLESHOOTING
B. For tissues
i. Immerse the collected fragments (~1 cm size) in ~5 ml of 
primary fixative in glass vials.
▲ CRITICAL STEP Tissue must be properly fixed 
immediately after interruption of blood supply. An 
interval of 10–15 min could be enough to cause artifacts. 
Do not ever allow the tissue to dry out. Handle the 
fragments gently to avoid mechanical damage.
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ii. After ~5 min, cut the fragments into small blocks of ~1 
mm × 1 mm in size, and then return them to the fixative 
for additional fixation (60 min) at room temperature. Very 
dense tissues may require longer fixation (2 h). For 
cutting, put a small pool of buffer on a piece of dental 
wax and add the tissue fragment. By using a razor blade, 
cut the tissue into small pieces.
iii. After fixation, remove the fixative using a pipette and 
wash the samples in 0.02 M PBS buffer.
2| Refrigerate the samples before further processing.
▲ CRITICAL STEP Because it is generally mildly fixed with 4% (wt/vol) 
paraformaldehyde, the samples should not be stored at 4 °C for a long time. 
Paraformaldehyde is not a strong cross-linker of proteins, and fixation can be 
reversed, damaging the structure. We usually proceed to the next step on the 
same or next day.
3| Make agar pellets by mixing the agar in 0.02 M (2% wt/vol) PBS and bringing it 
to a boil on a hot plate until the solution is completely dissolved, clear and just 
boiling. Leave it on the hot plate, while being stirred with a stir bar, so that the 
agar stays in a liquid state. Transfer the cell suspension to a microcentrifuge tube 
and spin it for 1 min (~9,500g) at room temperature. Carefully aspirate the small 
supernatant from the pelleted cells, quickly add hot agar and resuspend the cells 
using a toothpick. Spin the cells in a microcentrifuge for 1 min as before.
▲ CRITICAL STEP Cell suspensions must be pre-embedded in agar in order 
to be cut and processed. This step is not necessary for tissue fragments. In that 
case, proceed to Step 6.
▲ CRITICAL STEP If the agar is not adequately heated or if melted agar is not 
quickly added to the microcentrifuge tube, the cells will not re-form a pellet and 
will be spread out in the solidified agar.
? TROUBLESHOOTING
4| Chill the tubes on a bucket of ice for at least 20 min to allow the agar to solidify. 
After solidification, carefully remove the intact pellets from the microtubes 
using a razor blade and a pointed applicator stick. Use a small pool of buffer to 
help handling of the agar blocks and to avoid drying. Cut off any excess agar.
? TROUBLESHOOTING
5| Immerse the agar blocks containing the embedded cell suspensions or tissue 
fragments in a sucrose solution (30% wt/vol) in 0.02 M PBS overnight at 4 °C 
for cryoprotection.
6| Freeze the samples by immersing individual samples in a small amount of 
Tissue-Tek O.C.T. compound on a glass slide surface and carefully transferring 
the sample into a suitable cryomold filled with the same compound. 
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Alternatively (if a cryomold is not available), put a pool of O.C.T. compound on 
the surface of the cryostat specimen stage, transfer the sample, allow freezing 
and carefully detach the formed ice block from the specimen stage. The sample 
must be totally immersed in the embedding medium. If necessary, add additional 
O.C.T. compound during block solidification. Samples are then ready to be 
stored.
! CAUTION When you are handling liquid nitrogen, gloves, eye protection and 
closed shoes must be worn.
▲ CRITICAL STEP Freezing of agar pellets containing embedded cell 
suspensions requires special attention. In our experience, the best way to freeze 
these pellets is by holding (using a stick) the pellet upright (not horizontally) on 
the specimen stage. Thus, the area in which the cells are more concentrated will 
be more visible during sectioning.
? TROUBLESHOOTING
■ PAUSE POINT Store the samples in liquid nitrogen after careful labeling. 
Frozen samples can be stored for the long term (~3 years).
Immunolabeling ● TIMING ~5 h
▲ CRITICAL All steps are performed at room temperature.
7| Cut the frozen sections. Collect 10-μm-thick sections on Superfrost Plus glass 
slides (Fig. 3a,b). Before sectioning, label each slide with the appropriate code 
using a pencil (not a permanent pen) and, during sectioning, keep the slide 
outside the cryostat.
▲ CRITICAL STEP Before collecting all sections that will be immunolabeled, 
it is important to confirm that the cells and tissues are in adequate numbers and 
that they are visible on the sections by quickly staining one section with a 
histological stain. We use a toluidine blue solution that is also used for staining 
of TEM thick sections in our laboratory. Quickly dry a section on a glass slide 
by placing the slide on a slide warmer; cover it with a few drops of staining 
solution, rinse off excess stain gently with distilled water, dry the slide, 
coverslip with regular mounting medium and analyze it on a light microscope. If 
sufficient cells are not visible, cut extra sections and repeat this analysis. For 
immunolabeling, we usually collect four sections per slide for each sample. It is 
important to collect several sections because some of them may be lost during 
processing. Each section will correspond to one resin block, and therefore there 
will be several blocks from each sample by the end of the process. For each 
antigen to be immunolabeled, it is necessary to have a control for the primary 
antibody (replaced by an irrelevant antibody), and it is also desirable to have a 
slide in which the primary and/or the secondary antibody will be omitted. 
Therefore, for immunolocalization of one antigen in one sample, three slides 
from the same sample have to be prepared.
? TROUBLESHOOTING
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8| After sectioning, circle the sections with a diamond scriber pen to facilitate 
visualization of the section area, and allow the sections to adhere to the slide for 
~8 min at room temperature before subsequent steps.
9| Immerse the slides containing the sections in 0.02 M PBS for 5 min. This and 
other steps requiring slide immersion are performed in Coplin staining jars, as 
shown in Figure 3c. We use small staining jars that hold a maximum of eight 
slides. Avoid large jars, which will consume large volumes of solutions. 
Moreover, our experience is that each experiment should be done with a small 
number of conditions to facilitate processing.
10| Immerse the slides in PBS-glycine solution for 10 min. Discard PBS and add 
PBS-glycine solution in the staining jar (Fig. 3c).
▲ CRITICAL This step is important for fixative quenching.
11| Block nonspecific binding sites with PBS-gelatin-BSA buffer for 30 min. 
Discard the PBS-glycine solution and add the first blocking buffer (PBS-gelatin-
BSA) to the same jar containing the slides (Fig. 3c).
12| Block nonspecific binding sites with PBS-gelatin-BSA-NGS buffer for 30 min. 
Discard the first blocking buffer and add PBS-BSA-NGS to the same jar 
containing the slides (Fig. 3c).
13| Incubate the sections with primary antibody for 1 h. Prepare appropriate 
dilutions of the primary antibodies immediately before incubation. Antibodies 
are diluted in PBS-gelatin-BSA-NGS buffer, previously filtered in a coarse filter 
paper. A list of tested antibodies and their dilutions is shown in Table 1. 
Carefully place slides in a black moisture chamber, and cover each slide with the 
antibody solution (Fig. 3d,e). Cover the chamber with a black lid.
14| Block the sections with PBS-gelatin-BSA-NGS for 30 min. Discard the antibody 
solution; place the slides in a staining jar, as shown in Figure 2c, and add PBS-
gelatin-BSA-NGS buffer.
15| Incubate the sections with secondary antibody for 1 h. Prepare appropriate 
dilutions of the secondary antibodies (Nanogold) immediately before incubation. 
Antibodies are diluted in PBS-gelatin-BSA-NGS buffer, previously filtered in a 
coarse filter paper. Usually 1:100 dilution works well for our tested antibodies 
(Table 1). Carefully place the slides in a black moisture chamber and cover each 
slide with the antibody solution (Fig. 3d,e). Cover the chamber with a black lid.
16| Wash the sections in PBS-gelatin-BSA buffer for 3 × 10 min. Discard the 
antibody solution; place the slides in a clean staining jar and add PBS-gelatin-
BSA buffer.
17| Wash the sections in PBS for 3 × 5 min. Discard the PBS-gelatin-BSA buffer 
and add PBS to the same jar containing the slides.
18| Fix the sections in 2% (vol/vol) glutaraldehyde for 10 min. Move the slides to 
another clean staining jar and, inside a fume hood, add 2% glutaraldehyde.
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Silver enhancement of Nanogold particles ● TIMING ~1 h
▲ CRITICAL These steps should be performed at room temperature.
19| Wash the slides in distilled water for 5 × 5 min. Discard the fixative in an 
appropriate waste container. Place the slides in another clean jar and add 
distilled water.
20| In a darkroom, mix HQ Silver according to the manufacturer’s instructions (Fig. 
3f). Place the slides in a clear incubation chamber and cover each slide with the 
freshly prepared silver solution for 10 min at ~20 °C. ▲ CRITICAL STEP 
Incubation time affects the growth of gold particles, and therefore time must be 
rigorously controlled with a timer after covering each slide.
? TROUBLESHOOTING
21| Wash the slides in distilled water for 5 × 5 min by immersing them in a clean jar 
with distilled water.
22| Replace distilled water with 5% (wt/vol) sodium thiosulfate for 3 min.
EM processing: postfixation, contrasting and resin embedding ● TIMING ~2 h plus 16 h 
polymerization
▲ CRITICAL All steps are done at room temperature and in a fume hood.
23| Postfix the sections in osmium tetroxide for 10 min. Place the slides in an 
incubation chamber inside a fume hood. Cover the slides with the osmium 
solution and cover the chamber with a black lid or aluminum foil.
24| Wash the slides quickly in distilled water.
25| Stain en bloc with uranyl acetate for 5 min. Discard the osmium solution and 
cover slides with the uranyl acetate solution in the incubation chamber inside a 
fume hood. Cover with a black lid or aluminum foil.
26| Dehydrate the samples sequentially in 50, 70 and 95% (vol/vol) ethanol for 5 
min each, followed by 100% ethanol for 1 × 10 min. Dehydration is performed 
with the slides in a staining jar by replacing the alcohol series. The jar should be 
covered after immersing in 100% ethanol.
27| Infiltrate in a mixture of propylene oxide and Eponate (working solution) at a 
1:3 ratio for 15 min. This mixture should be prepared in a plastic tri-pour and 
covered before use. Infiltration is done by placing the slides in a clear incubation 
chamber and covering the sections with the resin mixture. Do not cover the 
incubation chamber with a lid.
28| Before embedding, stand the slides up for ~5 min to drain off the excess of 
infiltration mixture. Use a marker pen to make a circle on the bottom of each 
section (slide bottom) to facilitate identification of the section area when 
inverting the capsules. Embed the samples by inverting Eponate-filled plastic 
capsules over the slide-attached cell sections (Fig. 3g,h).
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▲ CRITICAL STEP Labels with the sample codes (written using a pencil or 
typed) should be inserted inside the capsules before filling them up with resin 
for appropriate identification. Put the labels on the bottom of the capsules.
29| Polymerize the samples at 60 °C in an oven for 16 h.
? TROUBLESHOOTING
30| Separate the Eponate blocks from the glass slides. Place the slides in a bucket 
containing a small amount of liquid nitrogen. Cover the bucket with a lid and 
wait for 1–2 min. Blocks will easily detach from the slides. If small pieces of 
glass remain on the block surface, immerse the block again in liquid nitrogen for 
some seconds. Remove the blocks from the plastic capsules by using a BEEM 
capsule press. Embedded sections will be at the block surface (Fig. 3i).
Thin sectioning of blocks and EM analysis ● TIMING ~1 h per sample
31| Under a stereomicroscope, localize the area of interest on the block surface (Fig. 
3i). Circle this area with a marker pen to facilitate localization, if necessary. By 
using a new razor blade that has been rinsed with alcohol and dried, trim the 
block face, to include the area of interest, forming a trapezoid shape ~0.5 mm 
wide and 0.7 mm high. Ensure that the top and bottom sides of the trimmed 
block are perfectly parallel, so that the sections will come off the knife in a 
ribbon.
32| Place the trimmed block in the ultramicrotome (Fig. 3j). Mount the diamond 
knife (1.8 mm, 45°), fill the water trough with filtered double-distilled water and 
align the block left to right and top to bottom so that the block face is perfectly 
parallel to the edge of the knife. Collect ultrathin sections of ~80 nm (silver or 
gold color) on uncoated 200-mesh copper grids, being careful to avoid folding 
of the sections. To help pick up thin sections onto each grid, use ultramicrotomy 
aid tools such as a loop (MATERIALS). Alternatively, a clean eyelash attached 
to a wooden stick is helpful to guide the sections. Prepare 2–3 grids from each 
block. Place grids in a small plastic Petri dish with a Whatman filter paper 
placed underneath the grid (Fig. 3k). Write the block code on the paper (Fig. 
3k). Cover it and allow it to dry.
? TROUBLESHOOTING
33| Enhance contrast of ultrathin sections (staining) by setting up a Petri dish with 
dental wax and placing drops of lead citrate on it. Place the grids onto drops 
(sections side down) for ~3–5 min. Remove the grids individually and rinse 
thoroughly with double-distilled water (ten dips each). Place the grids on the 
filter inside the same plastic Petri dish (Fig. 3k). We write the code Pb on the 
filter paper to distinguish between stained and unstained grids (Fig. 3k). We 
recommend keeping one unstained grid as reserve. The grids are now ready to 
be analyzed by TEM (Fig. 3l), or they can be stored in a plastic grid box for 
subsequent analysis.
? TROUBLESHOOTING
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■ PAUSE POINT Grids can be stored at room temperature for several months.
34| Perform standard TEM imaging and analysis of ultrathin sections. Check the 
quality of the immunolabeling.
? TROUBLESHOOTING
? TROUBLESHOOTING
Troubleshooting advice can be found in Table 2 and Figure 4.
● TIMING
Experiments are broken down into five phases, as shown in the flowchart in Figure 2.
Steps 1–6, sample preparation: ~15 h
Steps 7–18, immunolabeling: ~5 h
Steps 19–22, silver enhancement of Nanogold particles: ~1 h
Steps 23–30, EM processing: postfixation, contrasting and resin embedding: ~2 h plus 
16 h polymerization
Steps 31–34, thin sectioning of blocks and EM analysis: ~1 h per sample
ANTICIPATED RESULTS
Figure 4 shows excessive growth of gold particles and Figures 5–7 illustrate typical results 
obtained using this protocol. As shown in Figures 5 and 6 and Table 1, human leukocytes 
can be labeled for different antigens, and gold labels are observed as electron-dense particles 
associated with subcellular sites. We have used pre-embedding immunogold EM to 
investigate protein localization at cell surface microdomains (Figs. 1 and 5b; ref. 24), as well 
as cytoplasmic distribution of varied proteins, such as CD63 (ref. 17; Fig. 5a), MBP17 (Fig. 
6a) and PDI27 (Fig. 6b), within human leukocytes isolated from the peripheral blood. The 
technique also provided excellent immunolabeling for tissue antigens from experimental 
models (Fig. 7) and humans. As a control, cells incubated with an irrelevant primary 
antibody (Fig. 5c) or not incubated with primary or secondary antibodies (not shown) were 
imaged. Figures 1 and 5–7 also demonstrate that very good preservation and imaging of cell 
features, such as the nucleus, nuclear envelope, secretory granules, vesicles, lipid bodies, 
and endo-membranes and plasma membranes, can be expected using this protocol even in 
suboptimally fixed specimens. Analysis of labeling density in relation to these 
morphologically identifiable cell organelles and structures can be performed. Values are 
usually expressed as the number of gold particles per μm2 (organelle profiles) or per μm in 
case of membrane traces (reviewed in ref. 31). For example, quantitative analyses of gold 
nanoparticles using our methodology showed prominent accumulation of PDI on the nuclear 
envelope (Fig. 6b), with a mean level of labeling of 33.2 ± 9.5 gold particles/μm (mean ± 
s.e.m., n = 30 cell sections; ref. 27). Moreover, the quality of cell morphology obtained 
using this protocol is sufficiently adequate to uncover pathological and morphological 
changes. For example, Figure 5a illustrates the diagnostic appearance of a cell secretory 
process termed piecemeal degranulation, characterized by emptying of secretory granules in 
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response to an inflammatory stimulus32. The immunolabeling of specific proteins combined 
with the observation of cell morphological changes such as piecemeal degranulation by 
TEM are important for understanding secretion mechanisms of immune mediators during 
cell responses to inflammatory and allergic diseases33.
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Figure 1. 
Immunogold electron microscopy technique. (a,b) The protein of interest is investigated by 
immunolabeling with a primary antibody against the target molecule, followed by a 
secondary antibody (against the primary antibody) conjugated with gold nanoparticles. In 
our protocol, we use affinity-purified Fab fragments conjugated with 1.4-nm gold particles 
(Nanogold). In c, an electron micrograph shows subcellular sites of a human eosinophil 
leukocyte labeled for CD63. Cell surface microdomains and cytoplasmic secretory granules 
(Gr) and large vesicles (arrowheads) were labeled. Primary antibody was monoclonal mouse 
anti-human CD63, as described in Table 1. Secondary antibody was goat anti-mouse Fab 
fragment conjugated to 1.4-nm gold particles (1:100, Nanogold, Nanoprobes, cat. no. 2002). 
Cells were isolated from the blood of healthy donors as described23. Written informed 
consent was obtained from donors in accordance with the Declaration of Helsinki, and 
Institutional Review Board approval was obtained from the Beth Israel Deaconess Medical 
Center. N, nucleus. Scale bar, 700 nm.
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Figure 2. 
Flowchart showing the main stages and timing of pre-embedding immunogold EM 
procedure.
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Figure 3. 
Pre-embedding immunonanogold electron microscopy procedures. (a,b) Frozen cells or 
tissue are cut on a cryostat (10 μm-thick sections) and mounted on glass slides. (c) Slides are 
immersed in a sequence of blocking solutions using a Coplin staining jar. (d,e) Sections are 
incubated with the primary antibody, and then they are washed and incubated with the 
secondary antibody. (f) After a silver enhancement step, sections are processed for 
conventional electron microscopy. (g,h) Resin embedding is performed by inverting labeled, 
resin-filled plastic capsules over the slide-attached cell sections. (i) The resulting blocks, 
detached from the slides, show embedded sections at their surfaces. (j–l) Thin sections, cut 
on an ultramicrotome, are mounted on grids, stained with lead citrate (Pb) and analyzed on a 
transmission electron microscope (TEM).
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Figure 4. 
Example of excessive growth of gold particles (arrowheads) and background formation 
observed in the cytoplasm of a human eosinophil leukocyte after labeling for perilipin 2 
(PLIN2/ADRP) and incubation with silver enhancement components for 20 min, which was 
too long. Primary antibody was polyclonal guinea pig PLIN2/ADRP (reactivity human/
mouse/rat/bovine) (Fitzgerald, cat. no. 20R-AP002). Secondary antibody was goat anti-
guinea pig Fab fragment conjugated to 1.4-nm gold (1:100, Nanogold, Nanoprobes, cat. no. 
2055). Cells were isolated from the blood of healthy donors, as described in Melo et al.23. 
Written informed consent was obtained from donors in accordance with the Declaration of 
Helsinki, and Institutional Review Board approval was obtained from the Beth Israel 
Deaconess Medical Center. N, nucleus; LB, lipid body. Scale bar, 1.0 μm.
Melo et al. Page 23
Nat Protoc. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. 
Examples of pre-embedding immunonanogold labeling of human leukocytes. (a,b) Electron 
micrographs of eosinophils isolated from the peripheral blood and labeled for CD63 (a) or 
CD9 (b). Note the dense labeling at secretory granules (a, white arrowheads) and cell 
surface (b, black arrowheads). In c, a representative cell in which the primary antibody was 
replaced by an irrelevant antibody shows negative labeling. Primary antibodies were 
monoclonal mouse anti-human CD63 (a) and monoclonal mouse anti-human CD9 (b), as 
described in Table 1. In c, the irrelevant antibody was an isotype IgG1 control (BD 
Pharmingen). Secondary antibody was goat anti-mouse Fab fragment conjugated to 1.4-nm 
gold particles (1:100, Nanogold, Nanoprobes, cat. no. 2002). Cells were isolated from the 
blood of healthy donors, as described in Melo et al.23. Written informed consent was 
obtained from donors in accordance with the Declaration of Helsinki, and Institutional 
Review Board approval was obtained from the Beth Israel Deaconess Medical Center. N, 
nucleus. Scale bar, 1.5 μm.
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Figure 6. 
Human leukocyte subcellular sites immunolabeled for different antigens using pre-
embedding immunoEM. (a) Large vesiculotubular compartments (arrowheads) are positive 
for major basic protein (MBP), whereas (b) the nuclear envelope (arrowheads) is clearly 
labeled for protein disulfide isomerase (PDI). Primary antibodies were monoclonal mouse 
anti-human MBP (a) and monoclonal mouse anti-human PDI (b), as described in Table 1. 
Secondary antibody was goat anti-rabbit Fab fragment conjugated to 1.4-nm gold particles 
(1:100, Nanogold, Nanoprobes, cat. no. 2002). Cells were isolated from the blood of healthy 
donors, as described23. Written informed consent was obtained from donors in accordance 
with the Declaration of Helsinki, and Institutional Review Board approval was obtained 
from the Beth Israel Deaconess Medical Center. N, nucleus. Scale bars, 300 nm (a) and 1.1 
μm (b).
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Figure 7. 
Example of immunogold labeling of a mouse tissue (skin). Platelets with specific labeling at 
the surface of their α-granules (Gr) for nitric oxide synthase 3 (NOS3) are seen in the lumen 
of a blood vessel. Primary antibody was polyclonal rabbit anti-NOS3, as described in Table 
1. Secondary antibody was goat anti-rabbit Fab fragment conjugated to 1.4-nm gold 
particles (1:100, Nanogold, Nanoprobes, cat. no. 2004). Experimental protocols were 
approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess 
Medical Center. Scale bar, 500 nm.
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TABLE 2
Troubleshooting table.
Step Problem Possible reason and solution
1 Low number of cells in the 
pellets
Inadequate sample (cell suspension) collection. At least 3 million cells should be used for each pellet, but 
it is desirable to have more in case you lose cells or the pellet during processing. Make sure that the pellet 
can be visualized after fixation and before processing. Hypocellular suspensions may need pelleting, 
suspending and re-pelleting several times to make an appropriate pellet. Do not go ahead if you cannot 
see a good pellet. Re-collect sample with sufficient number of cells
3 Cells are spread in the agar 
pellet
Agar pellets were prepared too slowly or agar was not adequately heated. If cells are spread you will not 
be able to see them in adequate numbers on the electron microscope. Re-prepare another agar pellet and 
check if the pellet can be seen on the tube bottom (good pellet) and not spread in the tube wall (bad 
pellet)
4 Watery agar pellet (agar 
pellet dissolves when 
taken out from the tube)
Supernatant was not adequately taken out from the tube after centrifugation of the cell suspension (before 
adding liquid agar). Re-prepare another agar pellet
6, 7 Cells are poorly visible 
during cryostat microtomy
If the initial pellet was made with enough cells, this problem is probably due to inadequate freezing of 
the pellet (incorrect position). In our experience, pellets should be frozen intact and with the bottom area 
(in which the cells are more concentrated) upright. This will allow better visualization of the cells during 
cryostat microtomy and also will guarantee sufficient number of cells to be analyzed on the thin sections. 
It is preferable to have a small area containing high number of cells than a larger area with spread cells. 
In this case, you will see a low number of cells on the electron microscope. Re-prepare samples and 
freeze adequately
20 Excessive growing of gold 
particles and/or 
background staining (Fig. 
4)
The time of incubation with silver enhancement components is not optimized and probably was too long. 
Room temperature is too high. Silver enhancement is time-dependent. The enhancement time is the time 
required to obtain an adequate amplification of the Nanogold particles. Reduce the incubation time and 
test different times to find which one works best for your antigen. Check the room temperature. At 16 °C 
the developer solution is stable (no self-nucleation occurs) for at least 20 min; at 20 °C, the solution is 
stable for at least 15 min, and at 24 °C for at least 10 min. After this time, background staining may be 
observed. We established 10 min at ~20 °C as an ideal time period for our immunolabeling experiments
29 Resin blocks are soft Polymerization problems can occur owing to improper oven temperature setting, insufficient time of 
polymerization or oscillating oven temperature. It is very important to complete resin polymerization at a 
constant temperature of 60 °C. Extend the polymerization time for extra few hours at the same 
temperature. Other possible reasons include inadequate mixing of resin components or out-of-date 
accelerator. In these cases, sample processing should be repeated. Water condensation may also have 
contaminated the resin mixture. Keep the resin dry and do not open it until it reaches room temperature
32 Trouble in cutting high-
quality ultrathin sections 
for TEM
Ultramicrotomy requires high level of expertise and many hours of practice. Several factors such as knife 
angle, cutting speed, block size and water meniscus level can interfere in the procedure. One solution is 
to enlist the assistance of an experienced ultramicrotomist
33 Precipitation of lead on the 
thin sections
Contaminated lead citrate solution or inadequate washing of the grids after staining. Re-prepare the lead 
citrate solution. Rinse grids adequately using double-distilled water
34 Poor labeling Inadequate fixation or primary antibody concentration is not optimized. Start using just 4% (wt/vol) 
paraformaldehyde as a primary fixative. Test the primary antibody by using different concentrations. In 
our hands 1 h of incubation at room temperature is sufficient to label different antigens (Table 1) when 
the primary antibody concentration is adequate. Try a different antibody that has previously worked for 
immunocytochemistry studies
Excessive labeling Primary antibody concentration is not optimized (too high concentration). Test the primary antibody by 
using different dilutions
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